CN102260712B - 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 - Google Patents
溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 Download PDFInfo
- Publication number
- CN102260712B CN102260712B CN2011101433853A CN201110143385A CN102260712B CN 102260712 B CN102260712 B CN 102260712B CN 2011101433853 A CN2011101433853 A CN 2011101433853A CN 201110143385 A CN201110143385 A CN 201110143385A CN 102260712 B CN102260712 B CN 102260712B
- Authority
- CN
- China
- Prior art keywords
- sequence
- tumor
- gene
- gfp
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 55
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 34
- 238000010276 construction Methods 0.000 title claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 40
- 239000013598 vector Substances 0.000 claims abstract description 35
- 241000598171 Human adenovirus sp. Species 0.000 claims abstract description 22
- 230000006801 homologous recombination Effects 0.000 claims abstract description 16
- 238000002744 homologous recombination Methods 0.000 claims abstract description 16
- 239000003623 enhancer Substances 0.000 claims abstract description 13
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 12
- 239000013605 shuttle vector Substances 0.000 claims abstract description 10
- 108091026890 Coding region Proteins 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 50
- 230000014509 gene expression Effects 0.000 claims description 37
- 229960005091 chloramphenicol Drugs 0.000 claims description 24
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 19
- 238000010367 cloning Methods 0.000 claims description 17
- 229960000318 kanamycin Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 230000000174 oncolytic effect Effects 0.000 claims description 13
- 230000010076 replication Effects 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 229930027917 kanamycin Natural products 0.000 claims description 11
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 11
- 229930182823 kanamycin A Natural products 0.000 claims description 11
- 108020004414 DNA Proteins 0.000 claims description 10
- 229960000723 ampicillin Drugs 0.000 claims description 9
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 9
- 229920001817 Agar Polymers 0.000 claims description 6
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 claims description 6
- 239000008272 agar Substances 0.000 claims description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000004083 survival effect Effects 0.000 claims description 3
- 241000701190 Human adenovirus 11 Species 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 claims description 2
- 230000006909 anti-apoptosis Effects 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 230000004614 tumor growth Effects 0.000 abstract description 5
- 230000002476 tumorcidal effect Effects 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 3
- 238000005259 measurement Methods 0.000 abstract description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 48
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 101710094396 Hexon protein Proteins 0.000 description 2
- 102100039373 Membrane cofactor protein Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 101150013749 18.5 gene Proteins 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 108010084938 adenovirus receptor Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940105756 coagulation factor x Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000018732 detection of tumor cell Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101433853A CN102260712B (zh) | 2011-05-31 | 2011-05-31 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
| EP12792810.9A EP2716764B1 (en) | 2011-05-31 | 2012-02-29 | Construction and application of mutant type b human adenovirus ad11 having enhanced oncolytic power |
| JP2014513035A JP5943996B2 (ja) | 2011-05-31 | 2012-02-29 | 腫瘍溶解性強化Ｂ型ヒトアデノウイルスＡｄ１１突然変異体の構築とその応用 |
| PCT/CN2012/071757 WO2012163119A1 (zh) | 2011-05-31 | 2012-02-29 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
| US14/093,078 US9315827B2 (en) | 2011-05-31 | 2013-11-29 | Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same |
| US15/098,342 US9932606B2 (en) | 2011-05-31 | 2016-04-14 | Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same |
| US15/904,408 US10294493B2 (en) | 2011-05-31 | 2018-02-25 | Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101433853A CN102260712B (zh) | 2011-05-31 | 2011-05-31 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102260712A CN102260712A (zh) | 2011-11-30 |
| CN102260712B true CN102260712B (zh) | 2013-10-02 |
Family
ID=45007547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101433853A Active CN102260712B (zh) | 2011-05-31 | 2011-05-31 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9315827B2 (enExample) |
| EP (1) | EP2716764B1 (enExample) |
| JP (1) | JP5943996B2 (enExample) |
| CN (1) | CN102260712B (enExample) |
| WO (1) | WO2012163119A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102260712B (zh) * | 2011-05-31 | 2013-10-02 | 北京锤特生物科技有限公司 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| CN106591368A (zh) * | 2016-10-12 | 2017-04-26 | 郑州大学 | 携带il‑15r/il‑15融合基因的b亚群腺病毒11载体及其构建和用途 |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN110093323B (zh) * | 2018-01-31 | 2024-01-30 | 上海元宋生物技术有限公司 | 重组溶瘤腺病毒OncoAd-P28GANK-E1A-△E1B及其构建方法和应用 |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006040330A2 (en) * | 2004-10-13 | 2006-04-20 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
| CN101090974A (zh) * | 2004-11-16 | 2007-12-19 | 克鲁塞尔荷兰公司 | 包含重组病毒载体的多价疫苗 |
| WO2008107370A1 (en) * | 2007-03-02 | 2008-09-12 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE519854T1 (de) * | 1999-05-17 | 2011-08-15 | Crucell Holland Bv | Rekombinantes adenovirus auf basis von serotyp 48 (ad48). |
| CN102260712B (zh) * | 2011-05-31 | 2013-10-02 | 北京锤特生物科技有限公司 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
-
2011
- 2011-05-31 CN CN2011101433853A patent/CN102260712B/zh active Active
-
2012
- 2012-02-29 EP EP12792810.9A patent/EP2716764B1/en active Active
- 2012-02-29 JP JP2014513035A patent/JP5943996B2/ja active Active
- 2012-02-29 WO PCT/CN2012/071757 patent/WO2012163119A1/zh not_active Ceased
-
2013
- 2013-11-29 US US14/093,078 patent/US9315827B2/en active Active
-
2016
- 2016-04-14 US US15/098,342 patent/US9932606B2/en active Active
-
2018
- 2018-02-25 US US15/904,408 patent/US10294493B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006040330A2 (en) * | 2004-10-13 | 2006-04-20 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
| CN101090974A (zh) * | 2004-11-16 | 2007-12-19 | 克鲁塞尔荷兰公司 | 包含重组病毒载体的多价疫苗 |
| WO2008107370A1 (en) * | 2007-03-02 | 2008-09-12 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
Non-Patent Citations (2)
| Title |
|---|
| 刘辉等.携带RGD多肽的嵌合型腺病毒载体AD11-RGD-4C-EGFP的构建及其感染效率的研究.《第二军医大学学报》.1921,第31卷(第02期),178-182. |
| 携带RGD多肽的嵌合型腺病毒载体AD11-RGD-4C-EGFP的构建及其感染效率的研究;刘辉等;《第二军医大学学报》;19210516;第31卷(第02期);178-182 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US9315827B2 (en) | 2016-04-19 |
| US20180187214A1 (en) | 2018-07-05 |
| US20160222413A1 (en) | 2016-08-04 |
| CN102260712A (zh) | 2011-11-30 |
| JP2014523236A (ja) | 2014-09-11 |
| WO2012163119A1 (zh) | 2012-12-06 |
| EP2716764A1 (en) | 2014-04-09 |
| JP5943996B2 (ja) | 2016-07-05 |
| EP2716764B1 (en) | 2019-05-01 |
| US9932606B2 (en) | 2018-04-03 |
| EP2716764A4 (en) | 2015-01-14 |
| US10294493B2 (en) | 2019-05-21 |
| US20140088180A1 (en) | 2014-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5943996B2 (ja) | 腫瘍溶解性強化Ｂ型ヒトアデノウイルスＡｄ１１突然変異体の構築とその応用 | |
| CN103614416B (zh) | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 | |
| JP5746823B2 (ja) | Ｅ３−１９ｋタンパク質の小胞体保持ドメインに突然変異を有するアデノウイルス及び癌治療におけるその用途 | |
| US20240191255A1 (en) | Adenoviral Vectors | |
| JP2014523236A5 (enExample) | ||
| WO2018171103A1 (zh) | 可编程的溶瘤病毒疫苗系统及其应用 | |
| JP7441245B2 (ja) | 組換え腫瘍溶解性ウイルスとその調製方法、使用および医薬品 | |
| CN102844329A (zh) | 分离自猿腺病毒血清型19的六邻体、其高变区和使用其的嵌合型腺病毒 | |
| WO2021150635A1 (en) | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment | |
| CN102533657B (zh) | 一种人41型腺病毒(Ad41)包装细胞株及其应用 | |
| WO2020166727A1 (ja) | ヒト３５型アデノウイルスを基板とした腫瘍溶解性ウイルス | |
| CN113774031B (zh) | 一种复制型人腺病毒及其应用 | |
| CN120738288A (zh) | 重组腺病毒载体和基于该载体的复制型腺病毒重组体及其构建方法 | |
| WO2024251286A1 (zh) | 溶瘤性hsv-1临床分离株、定向进化株、感染性克隆及应用 | |
| CN117568286A (zh) | 痘苗病毒及其应用 | |
| Stepanenko et al. | Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD | |
| CN117701636A (zh) | 一种表达il-15超级激动剂的溶瘤病毒的构建方法与应用 | |
| Coughlan | Transductional retargeting of human adenovirus type 5 to ανβ6 integrin for cancer gene therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING CHUITE BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHENGZHOU UNIVERSITY Effective date: 20120213 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 450001 ZHENGZHOU, HENAN PROVINCE TO: 102206 CHANGPING, BEIJING |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20120213 Address after: 102206 room A215, Building 29, No. 1, life Garden Road, Beijing, Changping District Applicant after: Zhengzhou University Address before: 450001 Zhengzhou science and Technology Development Zone, Henan, No. 100 science Avenue Applicant before: Zhengzhou University |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |